Control (n=54) | Hypothermia (n=47) | |
Age, years (SD) | 55 (±12) | 58 (±10) |
Female gender, n (%) | 10 (19) | 10 (21) |
Hypertension, n (%) | 25 (46) | 13 (28) |
Diabetes, n (%) | 10 (19) | 5 (11) |
Dyslipidaemia, n (%) | 17 (32) | 10 (21) |
Current smoker, n (%) | 30 (56) | 26 (55) |
Familial history of CAD, n (%) | 12 (22) | 12 (25) |
Obesity, n (%) | 19 (35) | 10 (21) |
Weight, kg (SD) | 89 (±18) | 82 (±20) |
Body mass index (kg/m2), mean (SD) | 29.3 (±4.9) | 27.1 (±5.5) |
Previous medication | ||
Acetylsalicylic acid, n (%) | 6 (11) | 1 (2) |
Beta blocker, n (%) | 7 (13) | 4 (9) |
ACE-I/ARB, n (%) | 11 (20) | 8 (17) |
Statin, n (%) | 12 (22) | 3 (6) |
Initial sinus rhythm, n (%) | 49 (90) | 44 (94) |
Anterior wall infarction, n (%) | 25 (46) | 27 (57) |
Emergency therapy | ||
Acetylsalicylic acid, n (%) | 54 (100) | 47 (100) |
Heparin, n (%) | 54 (100) | 47 (100) |
Prasugrel/ticagrelor | 54 (100) | 47 (100) |
Nitroglycerin, n (%) | 12 (22) | 9 (19) |
Beta blocker, n (%) | 3 (6) | 0 (0) |
Infarct-related artery | ||
LAD*, n (%) | 24 (45) | 28 (60) |
Circumflex artery, n (%) | 4 (7) | 3 (6) |
Right coronary artery, n (%) | 25 (46) | 16 (34) |
Unknown, n (%) | 1 (2) | 0 (0) |
Multivessel disease, n (%) | 31 (59) | 22 (47) |
Initial TIMI† 0/1, n (%) | 43 (81) | 34 (72) |
No statistically significant difference between baseline variables (except for previous use of statins; p=0.03).
*Left anterior descending artery
†Thrombolysis in myocardial infarction grade flow.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; LAD, left anterior descending artery.